Literature DB >> 7852747

Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives.

Y K Lungershausen1, M Abbey, P J Nestel, P R Howe.   

Abstract

OBJECTIVE: To assess the effects of omega-3 (n-3) fatty acid supplementation on blood pressure and plasma lipids in hypertensives treated with diuretics or beta-blockers.
DESIGN: Double-blind placebo-controlled cross-over trial consisting of a 4-week run-in phase and two 6-week intervention phases. PATIENTS: A total of 43 patients of either sex taking a beta-blocker only (n = 29), a diuretic only (n = 3) or a beta-blocker plus diuretic (n = 11) for hypertension were recruited from general practice. One patient from the latter group was withdrawn.
METHODS: Seated blood pressure was measured every 2 weeks in the clinic with a Dinamap. After the run-in phase, participants were randomly assigned to take a supplement of either Omacor (85% n-3 fatty acid concentrate) or corn oil (four 1-g capsules/day) for 6 weeks, after which they crossed over to the other supplement. Fasted blood samples were taken at the end of each phase for lipid analysis. MAIN OUTCOME MEASURES: The within-individual differences in systolic and diastolic pressure and plasma lipids between Omacor and corn oil treatment.
RESULTS: Systolic/diastolic blood pressures measured during the run-in phase were normal (132 +/- 2/76 +/- 1 mmHg, n = 42) but decreased further with n-3 fatty acid supplementation. The mean within-individual difference in blood pressure compared with corn oil supplementation was 3.1 +/- 1.0/1.8 +/- 0.6 mmHg (P < 0.01). This was accompanied by a 21% reduction in plasma triglycerides (P < 0.01) and a 15% increase in high-density lipoprotein-2 cholesterol (P < 0.01) but there were no significant differences in total or low-density lipoprotein cholesterol.
CONCLUSION: The antihypertensive and hypotriglyceridaemic effects of n-3 fatty acid supplementation seen in the present study suggest that it may be a useful adjunct to antihypertensive therapy with beta-blockers or diuretics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852747

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  8 in total

Review 1.  n-3 fatty acids and lipoproteins: comparison of results from human and animal studies.

Authors:  W S Harris
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

Review 2.  Effects of diet on high-density lipoprotein cholesterol.

Authors:  Patty W Siri-Tarino
Journal:  Curr Atheroscler Rep       Date:  2011-12       Impact factor: 5.113

3.  Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.

Authors:  Ann C Skulas-Ray; Penny M Kris-Etherton; William S Harris; John P Vanden Heuvel; Paul R Wagner; Sheila G West
Journal:  Am J Clin Nutr       Date:  2010-12-15       Impact factor: 7.045

4.  Signaling pathways modulated by fish oil in salt-sensitive hypertension.

Authors:  Montserrat M Diaz Encarnacion; Gina M Warner; Catherine E Gray; Jingfei Cheng; Hesham K H Keryakos; Karl A Nath; Joseph P Grande
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-02

5.  Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study.

Authors:  Ann C Skulas-Ray; Penny M Kris-Etherton; William S Harris; Sheila G West
Journal:  Ann Behav Med       Date:  2012-12

Review 6.  A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.

Authors:  Clemens von Schacky
Journal:  Vasc Health Risk Manag       Date:  2006

7.  Study of urban community survey in India: growing trend of high prevalence of hypertension in a developing country.

Authors:  Shyamal Kumar Das; Kalyan Sanyal; Arindam Basu
Journal:  Int J Med Sci       Date:  2005-04-01       Impact factor: 3.738

8.  Omega-3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  ShiChun Shen; Chen Gong; KaiQin Jin; Lei Zhou; Yin Xiao; Likun Ma
Journal:  Front Nutr       Date:  2022-02-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.